<a href="https://laohu8.com/S/TEM">Tempus AI</a> Inc. Secures FDA 510(k) Clearance for AI-Driven Tempus ECG-Low EF Software to Enhance Cardiovascular Risk Detection
Tempus AI Inc. has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF software. This advanced AI-driven tool is designed to identify patients who may have a low left ventricular ejection fraction (LVEF), which is crucial for diagnosing serious cardiovascular conditions. This clearance marks the second FDA-approved ECG-AI device in Tempus' suite of cardiology tools, following the Tempus ECG-AF. The software is intended for use in clinical settings for patients aged 40 and above who are at risk of heart failure, and it aids in the detection of signs associated with low LVEF. This achievement underscores Tempus' commitment to leveraging AI to enhance precision medicine and patient care.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250716917042) on July 16, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。